Vitamin D receptor activation in a diabetic-like environment: Potential role in the activity of the endothelial pro-inflammatory and thioredoxin pathways

Journal of Steroid Biochemistry and Molecular Biology

Volumn 132, Issue 1-2, 2012, Pages 1-7

  Zitman Gal, T ^a   Golan, E ^a,b   Green, J ^a   Bernheim, J ^a,b   Benchetrit, S ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Calcitriol; Diabetes; Endothelial cells; Paricalcitol; Thioredoxin; Vitamin D

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CALCITRIOL; GLUCOSE; INTERLEUKIN 6; INTERLEUKIN 8; PARICALCITOL; PROTEIN P50; SYNAPTOTAGMIN I; THIOREDOXIN; THIOREDOXIN INTERACTING PROTEIN;

ARTICLE; DIABETES MELLITUS; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANTIGENS, NEOPLASM; CALCITRIOL; CARRIER PROTEINS; CELLS, CULTURED; DIABETES MELLITUS; ERGOCALCIFEROLS; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B P50 SUBUNIT; RECEPTORS, CALCITRIOL; RNA, MESSENGER; SERUM ALBUMIN; THIOREDOXIN-DISULFIDE REDUCTASE; THIOREDOXINS;

EID: 84864423786     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2012.04.003     Document Type: Article

References (40)

1. R. Madonna, and R. De Caterina Cellular and molecular mechanisms of vascular injury in diabetes. Part I. Pathways of vascular disease in diabetes Vascular Pharmacology 54 2011 68 74
2. A. Puddu, and G.L. Viviani Advanced glycation endproducts and diabetes. Beyond vascular complications Endocrine, Metabolic & Immune Disorders Drug Targets 11 2011 132 140
3. W. Bakker, E.C. Eringa, P. Sipkema, and V.W.M. van Hinsbergh Endothelial dysfunction and diabetes: role of hyperglycaemia, impaired insulin signalling and obesity Cell and Tissue Research 335 2009 165 189
4. D.P. Barlovic, A. Soro-Paavonen, and K.A. Jandeleit-Dahm. RAGE biology, atherosclerosis and diabetes Clinical Science (London) 121 2011 43 55
5. M. Daroux, G. Prévost, H. Maillard-Lefebvre, C. Gaxatte, V.D. D'Agati, A.M. Schmidt, and E. Boulanger Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies Diabetes & Metabolism 36 2010 1 10
6. A. Goldin, J.A. Beckman, A.M. Schmidt, and M.A. Creager Advanced glycation end products sparking the development of diabetic vascular injury Circulation 114 2006 597 605 (Pubitemid 44199649)
7. D.S.C. Raj, D. Choudhury, T.C. Welboume, and M. Levi Advanced glycation end products: a nephrologist's perspective American Journal of Kidney Diseases 35 2000 365 380
8. J.L. Wautier, and P.J. Guillausseau Advanced glycation end products, their receptors and diabetic angiopathy Diabetes & Metabolism 27 2001 535 542 (Pubitemid 33051702)
9. G. Rashid, S. Benchetrit, D. Fishman, and J. Bernheim Effect of advanced glycation end products (AGEs) on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells Kidney International 66 2004 1099 1106 (Pubitemid 39121015)
10. Y. Talmor-Barkan, J. Bernheim, J. Green, S. Benchetrit, and G. Rashid Calcitriol counteracts endothelial cell pro-inflammatory processes in a chronic kidney disease-like environment The Journal of Steroid Biochemistry and Molecular Biology 124 2011 19 24
11. T. Zitman-Gal, J. Green, M. Pasmanik-Chor, V. Oron-Karni, and J. Bernheim Endothelial pro-atherosclerotic response to extracellular diabetic-like environment: possible role of thioredoxin-interacting protein Nephrology, Dialysis, Transplantation 25 2010 2141 2149
12. P.C. Schulze, J. Yoshioka, T. Takahashi, Z. He, G.L. King, and R.T. Lee Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein Journal of Biological Chemistry 279 2004 30369 30374 (Pubitemid 38937964)
13. T. Hirota, T. Okano, K. Kokame, H. Shirotani-Ikejima, T. Miyata, and Y. Fukada Glucose down-regulates Per1 and Per2 mRNA levels and induces circadian gene expression in cultured Rat-1 fibroblasts Journal of Biological Chemistry 277 2002 44244 44251 (Pubitemid 36157857)
14. A. Shalev, C.A. Pise-Masison, M. Radonovich, S.C. Hoffmann, B. Hirshberg, J.N. Brady, and D.M. Harlan Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGFbeta signaling pathway Endocrinology 143 2002 3695 3698 (Pubitemid 34925747)
15. S. Fang, Y. Jin, H. Zheng, J. Yan, Y. Cui, H. Bi, H. Jia, H. Zhang, Y. Wang, L. Na, X. Gao, and H. Zhou High glucose condition upregulated Txnip expression level in rat mesangial cells through ROS/MEK/MAPK pathway Molecular and Cellular Biochemistry 347 2011 175 182
16. J. Chen, H. Cha-Molstad, A. Szabo, and A. Shalev Diabetes induces and calcium channel blockers prevent cardiac expression of pro-apoptotic thioredoxin-interacting protein American Journal of Physiology. Endocrinology and Metabolism 296 2009 1133 1139
17. H. Yamawaki Thioredoxin: a multifunctional antioxidant enzyme in kidney, heart and vessels Current Opinion in Nephrology and Hypertension 14 2005 149 153 (Pubitemid 40396868)
18. R.J. Bernardi, C.S. Johnson, R.A. Modzelewski, and D.L. Trump Antiproliferative effects of 1α,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells Endocrinology 143 2002 2508 2514 (Pubitemid 34701313)
19. E.S. Ford, U.A. Ajani, L.C. McGuire, and S. Liu Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults Diabetes Care 28 2005 1228 1230 (Pubitemid 40616645)
20. M.F. Holick Vitamin D deficiency New England Journal of Medicine 357 2007 266 281
21. W.D. Fraser Hyperparathyroidism Lancet 374 2009 145 158
22. K.J. Martin, and E.A. González Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism Seminars in Nephrology 24 2004 456 459 (Pubitemid 39361053)
23. D. De Zeeuw, R. Agarwal, M. Amdahl, P. Audhya, D. Coyne, T. Garimella, H.H. Parving, Y. Pritchett, G. Remuzzi, E. Ritz, and D. Andress Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial Lancet 376 2010 1543 1551
24. M.C. Monier-Faugere, H. Mawad, and H.H. Malluche Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease Clinical Journal of the American Society of Nephrology 2 2007 1255 1260
25. M.S. Petri, T.E. Harrell, G.G. Schwartz, and D.C. Sane Production of plasminogen activator inhibitor-1 (PAI-1) by endothelial cells: differential responses to calcitriol and paricalcitol Journal of Thrombosis and Haemostasis 2 2004 2266 2267 (Pubitemid 40185792)
26. M. Igarashi, H. Wakasaki, N. Takahara, H. Ishii, Z.Y. Jiang, T. Yamauchi, K. Kuboki, M. Meier, C.J. Rhodes, and G.L. King Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways Journal of Clinical Investigation 103 1999 185 195 (Pubitemid 29053136)
27. W.A. Wilmer, C.L. Dixon, and C. Hebert Chronic exposure of human mesangial cells to high glucose environment activates the p38 MAPK pathway Kidney International 60 2001 858 871 (Pubitemid 34205786)
28. L. Perrone, T.S. Devi, K. Hosoya, T. Terasaki, and L.P. Singh Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions Journal of Cellular Physiology 221 2009 262 272
29. F. Turturro, E. Friday, and T. Welbourne Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxin-interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231 BMC Cancer 7 2007 96
30. S. Rani, J.P. Mehta, N. Barron, P. Doolan, P.B. Jeppesen, M. Clynes, and L. O'Driscoll. Decreasing Txnip mRNA and protein levels in pancreatic MIN6 cells reduces reactive oxygen species and restores glucose regulated insulin secretion Cellular Physiology and Biochemistry 25 2010 667 674
31. Y. Shi, Y. Ren, L. Zhao, C. Du, Y. Wang, Y. Zhang, Y. Li, S. Zhao, and H. Duan Knockdown of thioredoxin interacting protein attenuates high glucose-induced apoptosis and activation of ASK1 in mouse mesangial cells FEBS Letters 585 2011 1789 1795
32. J. Altschmied, and J. Haendeler Thioredoxin-1 and endothelial cell aging: role in cardiovascular diseases Antioxidants & Redox Signaling 11 2009 1733 1740
33. D. Mustacich, and G. Powis Thioredoxin reductase The Biochemical Journal 346 2000 1 8 (Pubitemid 30113812)
34. P. Patwari, W.A. Chutkow, K. Cummings, V.L. Verstraeten, J. Lammerding, E.R. Schreiter, and R.T. Lee Thioredoxin-independent regulation of metabolism by the alpha-arrestin proteins Journal of Biological Chemistry 284 2009 24996 25003
35. L.G. Danescu, S. Levy, and J. Levy Vitamin D and diabetes mellitus Endocrinology 35 2009 11 17
36. J. Cunningham, and D. Zehnder New Vitamin D analogs and changing therapeutic paradigms Kidney International 79 2011 702 707
37. J.R. Wu-Wong, M. Nakane, J. Ma, X. Ruan, and P.E. Kroeger Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells Atherosclerosis 186 2006 20 28
38. J.L. Finch, M. Tokumoto, H. Nakamura, W. Yao, M. Shahnazari, N. Lane, and E. Slatopolsky Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease American Journal of Physiology. Renal Physiology 298 2010 1315 1322
39. C. Mathieu, C. Gysemans, A. Giulietti, and R. Bouillon Vitamin D and diabetes Diabetologia 48 2005 1247 1257 (Pubitemid 41186086)
40. T. Takiishi, C. Gysemans, R. Bouillon, and C. Mathieu Vitamin D and diabetes Endocrinology and Metabolism Clinics of North America 39 2010 419 446